Ontology type: schema:ScholarlyArticle
2013-11-04
AUTHORSC. W. Ritchie, J. Bajwa, G. Coleman, K. Hope, R. W. Jones, M. Lawton, M. Marven, P. Passmore
ABSTRACTSynaptic loss correlates closely with cognitive deficits in Alzheimer’s disease and represents a new target for intervention. Souvenaid® is the first medical nutrition product to be designed to support synapse formation and function in early Alzheimer’s disease, and has undergone an extensive, 12-year development programme. The relatively large amount of clinical data available for Souvenaid® is unusual for a medical nutrition product. Souvenaid® contains omega-3 polyunsaturated fatty acids (docosahexaenoic acid and eicosapentaenoic acid), uridine (as uridine monophosphate) and choline which are nutritional precursors required for synaptic membrane phospholipid synthesis, together with phospholipids and other cofactors. Souvenaid® has demonstrated cognitive benefits in patients with mild Alzheimer’s disease but not in patients with mild-to-moderate Alzheimer’s disease. Two randomised, double-blind, controlled trials (duration 12 and 24 weeks) in patients with mild Alzheimer’s disease untreated with acetylcholinesterase inhibitors and/or memantine have demonstrated that Souvenaid® is well tolerated and improves episodic memory performance. The daily intake of Souvenaid® has not been associated with any harmful effects or interactions with medications and none are anticipated. The ongoing, 24-month, European Union-funded LipiDiDiet trial in subjects with prodromal Alzheimer’s disease is evaluating the potential benefits of Souvenaid® on memory and in slowing progression to Alzheimer’s dementia. If Souvenaid® induces synaptogenesis and improved synaptic function, it may provide benefits in other clinical conditions characterised by neurodegeneration. A number of trials are ongoing and planned to evaluate the potential wider benefits of Souvenaid®. More... »
PAGES291-299
http://scigraph.springernature.com/pub.10.1007/s12603-013-0411-2
DOIhttp://dx.doi.org/10.1007/s12603-013-0411-2
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1034591338
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/24626757
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Clinical Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1111",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Nutrition and Dietetics",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Alzheimer Disease",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Choline",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Cholinesterase Inhibitors",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Disease Progression",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Docosahexaenoic Acids",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Double-Blind Method",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Eicosapentaenoic Acid",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "European Union",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Female",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Male",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Memantine",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Memory, Episodic",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Prodromal Symptoms",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Randomized Controlled Trials as Topic",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Synapses",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Uridine Monophosphate",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Department of Medicine, Imperial College, London, UK",
"id": "http://www.grid.ac/institutes/grid.7445.2",
"name": [
"Department of Medicine, Imperial College, London, UK",
"Department of Medicine, Imperial College, London, UK"
],
"type": "Organization"
},
"familyName": "Ritchie",
"givenName": "C. W.",
"id": "sg:person.0715446716.30",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0715446716.30"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Conway Medical Centre, Plumstead, London, UK",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Conway Medical Centre, Plumstead, London, UK"
],
"type": "Organization"
},
"familyName": "Bajwa",
"givenName": "J.",
"type": "Person"
},
{
"affiliation": {
"alternateName": "London, UK",
"id": "http://www.grid.ac/institutes/None",
"name": [
"London, UK"
],
"type": "Organization"
},
"familyName": "Coleman",
"givenName": "G.",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Dementia Services Development Centre, University of Stirling, Stirling, UK",
"id": "http://www.grid.ac/institutes/grid.11918.30",
"name": [
"Dementia Services Development Centre, University of Stirling, Stirling, UK"
],
"type": "Organization"
},
"familyName": "Hope",
"givenName": "K.",
"id": "sg:person.01056304631.29",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01056304631.29"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Research Institute for the Care of Older People, Royal United Hospital, Bath, UK",
"id": "http://www.grid.ac/institutes/grid.416091.b",
"name": [
"Research Institute for the Care of Older People, Royal United Hospital, Bath, UK"
],
"type": "Organization"
},
"familyName": "Jones",
"givenName": "R. W.",
"id": "sg:person.01320561246.23",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320561246.23"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "London, UK",
"id": "http://www.grid.ac/institutes/None",
"name": [
"London, UK"
],
"type": "Organization"
},
"familyName": "Lawton",
"givenName": "M.",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Oxford Health NHS Foundation Trust, Oxford, UK",
"id": "http://www.grid.ac/institutes/grid.451190.8",
"name": [
"Oxford Health NHS Foundation Trust, Oxford, UK"
],
"type": "Organization"
},
"familyName": "Marven",
"givenName": "M.",
"id": "sg:person.0603772166.26",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0603772166.26"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Centre for Public Health, Queens University, Belfast, UK",
"id": "http://www.grid.ac/institutes/grid.4777.3",
"name": [
"Centre for Public Health, Queens University, Belfast, UK"
],
"type": "Organization"
},
"familyName": "Passmore",
"givenName": "P.",
"id": "sg:person.0751705456.81",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0751705456.81"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1023/a:1025628925796",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1050886881",
"https://doi.org/10.1023/a:1025628925796"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s11920-013-0367-2",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1017268113",
"https://doi.org/10.1007/s11920-013-0367-2"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1023/a:1008852127668",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1008832069",
"https://doi.org/10.1023/a:1008852127668"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s12603-011-0339-3",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1044372203",
"https://doi.org/10.1007/s12603-011-0339-3"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s10616-006-9038-z",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1045801968",
"https://doi.org/10.1007/s10616-006-9038-z"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1023/a:1011603916962",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1047542537",
"https://doi.org/10.1023/a:1011603916962"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s12603-012-0385-5",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1009103358",
"https://doi.org/10.1007/s12603-012-0385-5"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/nature04598",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1008587713",
"https://doi.org/10.1038/nature04598"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00702-003-0007-9",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1042189844",
"https://doi.org/10.1007/s00702-003-0007-9"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/nn1908",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1041228661",
"https://doi.org/10.1038/nn1908"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s12603-012-0097-x",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1040649409",
"https://doi.org/10.1007/s12603-012-0097-x"
],
"type": "CreativeWork"
}
],
"datePublished": "2013-11-04",
"datePublishedReg": "2013-11-04",
"description": "Synaptic loss correlates closely with cognitive deficits in Alzheimer\u2019s disease and represents a new target for intervention. Souvenaid\u00ae is the first medical nutrition product to be designed to support synapse formation and function in early Alzheimer\u2019s disease, and has undergone an extensive, 12-year development programme. The relatively large amount of clinical data available for Souvenaid\u00ae is unusual for a medical nutrition product. Souvenaid\u00ae contains omega-3 polyunsaturated fatty acids (docosahexaenoic acid and eicosapentaenoic acid), uridine (as uridine monophosphate) and choline which are nutritional precursors required for synaptic membrane phospholipid synthesis, together with phospholipids and other cofactors. Souvenaid\u00ae has demonstrated cognitive benefits in patients with mild Alzheimer\u2019s disease but not in patients with mild-to-moderate Alzheimer\u2019s disease. Two randomised, double-blind, controlled trials (duration 12 and 24 weeks) in patients with mild Alzheimer\u2019s disease untreated with acetylcholinesterase inhibitors and/or memantine have demonstrated that Souvenaid\u00ae is well tolerated and improves episodic memory performance. The daily intake of Souvenaid\u00ae has not been associated with any harmful effects or interactions with medications and none are anticipated. The ongoing, 24-month, European Union-funded LipiDiDiet trial in subjects with prodromal Alzheimer\u2019s disease is evaluating the potential benefits of Souvenaid\u00ae on memory and in slowing progression to Alzheimer\u2019s dementia. If Souvenaid\u00ae induces synaptogenesis and improved synaptic function, it may provide benefits in other clinical conditions characterised by neurodegeneration. A number of trials are ongoing and planned to evaluate the potential wider benefits of Souvenaid\u00ae.",
"genre": "article",
"id": "sg:pub.10.1007/s12603-013-0411-2",
"inLanguage": "en",
"isAccessibleForFree": false,
"isPartOf": [
{
"id": "sg:journal.1021574",
"issn": [
"1279-7707",
"1760-4788"
],
"name": "The journal of nutrition, health & aging",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "3",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "18"
}
],
"keywords": [
"early Alzheimer's disease",
"Alzheimer's disease",
"mild Alzheimer's disease",
"medical nutrition products",
"nutrition products",
"moderate Alzheimer's disease",
"prodromal Alzheimer's disease",
"LipiDiDiet trial",
"synaptic loss",
"Controlled Trials",
"Souvenaid",
"clinical data",
"clinical conditions",
"Alzheimer's dementia",
"synaptic function",
"synapse formation",
"cognitive deficits",
"daily intake",
"disease",
"patients",
"nutritional precursors",
"episodic memory performance",
"acetylcholinesterase inhibitors",
"new targets",
"trials",
"number of trials",
"dementia",
"cognitive benefits",
"fatty acids",
"harmful effects",
"potential benefits",
"phospholipid synthesis",
"membrane phospholipid synthesis",
"memory performance",
"medications",
"memantine",
"mild",
"synaptogenesis",
"intake",
"neurodegeneration",
"progression",
"benefits",
"intervention",
"inhibitors",
"deficits",
"choline",
"subjects",
"phospholipids",
"function",
"target",
"management",
"loss",
"uridine",
"effect",
"acid",
"wider benefits",
"program",
"potential wider benefits",
"data",
"cofactor",
"number",
"development programs",
"large amount",
"memory",
"products",
"amount",
"precursors",
"conditions",
"new approach",
"synthesis",
"formation",
"interaction",
"approach",
"Union",
"European Union",
"performance",
"first medical nutrition product",
"synaptic membrane phospholipid synthesis",
"induces synaptogenesis"
],
"name": "Souvenaid\u00ae: A new approach to management of early Alzheimer\u2019s disease",
"pagination": "291-299",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1034591338"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1007/s12603-013-0411-2"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"24626757"
]
}
],
"sameAs": [
"https://doi.org/10.1007/s12603-013-0411-2",
"https://app.dimensions.ai/details/publication/pub.1034591338"
],
"sdDataset": "articles",
"sdDatePublished": "2022-01-01T18:29",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_586.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1007/s12603-013-0411-2"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12603-013-0411-2'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12603-013-0411-2'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12603-013-0411-2'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12603-013-0411-2'
This table displays all metadata directly associated to this object as RDF triples.
320 TRIPLES
22 PREDICATES
134 URIs
114 LITERALS
24 BLANK NODES